Key Takeaway: The presentation at AD/PD 2025 highlighted the positive effects of CT1812 treatment on plasma biomarkers, particularly in patients with lower p-tau217 levels. These findings suggest that the treatment aligns with clinical benefits for individuals suffering from mild-to-moderate Alzheimer's disease. The results indicate a promising avenue for further research and potential therapeutic applications.
Price reaction · baseline $0.4208 (2025-03-31 close) · hit pre-market · 2 other CGTX headline(s) in the window, move may be shared
day 0 close
-6.8%
day 1
-1.9%
day 3 · peak
-15.8%
Market Sentiment Analysis
POSITIVE FACTORS
CT1812 treatment shows a positive impact on plasma biomarkers.
Clinical benefits observed in mild-to-moderate Alzheimer's patients.
Results align with improvements in specific patient subgroups.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Hamby ME, Kavanagh S, Di Caro V, et al. Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in Mild-to-Moderate AD Patients . Poster presented at AD/PD 2025 ; Vienna, Austria
Frequently Asked Questions
What is the focus of the CT1812 study?
The study focuses on the impact of CT1812 treatment on plasma biomarkers in Alzheimer's patients.
What subgroup showed positive results with CT1812?
The lower p-tau217 subgroup of mild-to-moderate Alzheimer's patients showed positive results.
Where was the CT1812 study presented?
The study was presented at the AD/PD 2025 conference in Vienna, Austria.
What are the clinical benefits of CT1812?
CT1812 treatment aligns with observed clinical benefits in patients with mild-to-moderate Alzheimer's.